Zimmer Biomet Holdings, Inc. (ZBH) EV/Sales Ratio: 2.89x
Is Zimmer Biomet Holdings, Inc.’s EV/Sales ratio high or low?
Zimmer Biomet Holdings, Inc.'s EV/Sales ratio of 2.89x is 28% below its 5-year average of 4.02x, near the low end of its 5-year range (2.69x–6.00x).
As of Saturday, June 20, 2026. 8.54% below its 12-month average of 3.16x.
ZBH EV/Sales Ratio Chart
ZBH Average EV/Sales Ratio Chart
ZBH Current vs Average EV/Sales Ratio Chart
ZBH EV/Sales Ratio Metrics
EV/SALES RATIO
2.89x
EV/SALES RATIO AVG TTM
3.16x
EV/SALES RATIO AVG 3Y
3.65x
EV/SALES RATIO AVG 5Y
3.99x
EV/SALES RATIO AVG 10Y
4.20x
EV/SALES RATIO AVG 15Y
4.05x
EV/SALES RATIO AVG 20Y
3.94x
CURRENT VS TTM AVG
-8.54%
CURRENT VS 3Y AVG
-20.92%
CURRENT VS 5Y AVG
-27.56%
CURRENT VS 10Y AVG
-31.25%
CURRENT VS 15Y AVG
-28.57%
CURRENT VS 20Y AVG
-26.67%
ZBH Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. (ZBH) | $17.02B | 2.89x | 3.16x | 3.65x | 3.99x |
| Hologic, Inc. (HOLX)vs › | $16.97B | 4.25x | 4.02x | 4.39x | 4.15x |
| DaVita Inc. (DVA)vs › | $13.34B | 1.94x | 1.81x | 1.84x | 1.85x |
| Medpace Holdings, Inc. (MEDP)vs › | $13.14B | 4.78x | 6.02x | 5.55x | 5.39x |
| Solventum Corporation (SOLV)vs › | $13.06B | 2.15x | 2.18x | 2.26x | 2.26x |
| Labcorp Holdings Inc. (LH)vs › | $20.98B | 1.94x | 2.09x | 2.00x | 1.88x |
| Align Technology, Inc. (ALGN)vs › | $13.04B | 2.95x | 2.72x | 4.05x | 5.85x |
| The Cooper Companies, Inc. (COO)vs › | $12.85B | 3.59x | 4.14x | 5.15x | 5.79x |
| United Therapeutics Corporation (UTHR)vs › | $22.78B | 7.65x | 6.53x | 5.73x | 5.78x |
| Revvity, Inc. (RVTY)vs › | $11.16B | 4.71x | 4.79x | 5.55x | 5.57x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
Zimmer Biomet Holdings, Inc. EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zimmer Biomet Holdings, Inc. EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Zimmer Biomet Holdings, Inc. (ZBH)?
- The EV/Sales ratio for ZBH stock is 2.89x.
- Is Zimmer Biomet Holdings, Inc.'s EV/Sales ratio high or low?
- Zimmer Biomet Holdings, Inc.'s EV/Sales ratio of 2.89x is 28% below its 5-year average of 4.02x, near the low end of its 5-year range (2.69x–6.00x).
- What is the TTM average EV/Sales ratio for Zimmer Biomet Holdings, Inc. (ZBH)?
- The TTM average EV/Sales ratio for ZBH stock is 3.16x.
- What is the 3Y average EV/Sales ratio for Zimmer Biomet Holdings, Inc. (ZBH)?
- The 3Y average EV/Sales ratio for ZBH stock is 3.65x.
- What is the 5Y average EV/Sales ratio for Zimmer Biomet Holdings, Inc. (ZBH)?
- The 5Y average EV/Sales ratio for ZBH stock is 3.99x.
- What is the 10Y average EV/Sales ratio for Zimmer Biomet Holdings, Inc. (ZBH)?
- The 10Y average EV/Sales ratio for ZBH stock is 4.20x.
- What is the 15Y average EV/Sales ratio for Zimmer Biomet Holdings, Inc. (ZBH)?
- The 15Y average EV/Sales ratio for ZBH stock is 4.05x.
- What is the 20Y average EV/Sales ratio for Zimmer Biomet Holdings, Inc. (ZBH)?
- The 20Y average EV/Sales ratio for ZBH stock is 3.94x.
Zimmer Biomet Holdings, Inc. EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-18 | 2.89x |
| 2026-06-17 | 2.87x |
| 2026-06-16 | 2.92x |
| 2026-06-15 | 2.89x |
| 2026-06-12 | 2.90x |
| 2026-06-11 | 2.87x |
| 2026-06-10 | 2.89x |
| 2026-06-09 | 2.92x |
| 2026-06-08 | 2.87x |
| 2026-06-05 | 2.87x |
| 2026-06-04 | 2.86x |
| 2026-06-03 | 2.82x |
| 2026-06-02 | 2.79x |
| 2026-06-01 | 2.77x |
| 2026-05-29 | 2.75x |
| 2026-05-28 | 2.77x |
| 2026-05-27 | 2.76x |
| 2026-05-26 | 2.80x |
| 2026-05-22 | 2.83x |
| 2026-05-21 | 2.82x |
| 2026-05-20 | 2.83x |
| 2026-05-19 | 2.84x |
| 2026-05-18 | 2.82x |
| 2026-05-15 | 2.79x |
| 2026-05-14 | 2.76x |
| 2026-05-13 | 2.76x |
| 2026-05-12 | 2.78x |
| 2026-05-11 | 2.69x |
| 2026-05-08 | 2.75x |
| 2026-05-07 | 2.78x |
| 2026-05-06 | 2.77x |
| 2026-05-05 | 2.77x |
| 2026-05-04 | 2.76x |
| 2026-05-01 | 2.77x |
| 2026-04-30 | 2.83x |
| 2026-04-29 | 2.77x |
| 2026-04-28 | 2.83x |
| 2026-04-27 | 3.07x |
| 2026-04-24 | 3.04x |
| 2026-04-23 | 3.07x |
| 2026-04-22 | 3.08x |
| 2026-04-21 | 3.07x |
| 2026-04-20 | 3.14x |
| 2026-04-17 | 3.12x |
| 2026-04-16 | 3.12x |
| 2026-04-15 | 3.11x |
| 2026-04-14 | 3.16x |
| 2026-04-13 | 3.14x |
| 2026-04-10 | 3.08x |
| 2026-04-09 | 3.08x |
| 2026-04-08 | 3.08x |
| 2026-04-07 | 3.04x |
| 2026-04-06 | 3.03x |
| 2026-04-02 | 3.03x |
| 2026-04-01 | 3.03x |
| 2026-03-31 | 3.02x |
| 2026-03-30 | 2.97x |
| 2026-03-27 | 2.97x |
| 2026-03-26 | 2.99x |
| 2026-03-25 | 2.95x |
| 2026-03-24 | 2.92x |
| 2026-03-23 | 2.95x |
| 2026-03-20 | 2.96x |
| 2026-03-19 | 3.00x |
| 2026-03-18 | 2.99x |
| 2026-03-17 | 3.07x |
| 2026-03-16 | 3.09x |
| 2026-03-13 | 3.08x |
| 2026-03-12 | 3.07x |
| 2026-03-11 | 3.10x |
| 2026-03-10 | 3.05x |
| 2026-03-09 | 3.09x |
| 2026-03-06 | 3.11x |
| 2026-03-05 | 3.09x |
| 2026-03-04 | 3.15x |
| 2026-03-03 | 3.20x |
| 2026-03-02 | 3.24x |
| 2026-02-27 | 3.21x |
| 2026-02-26 | 3.27x |
| 2026-02-25 | 3.24x |
| 2026-02-24 | 3.24x |
| 2026-02-23 | 3.24x |
| 2026-02-20 | 3.22x |
| 2026-02-19 | 3.23x |
| 2026-02-18 | 3.29x |
| 2026-02-17 | 3.26x |
| 2026-02-13 | 3.24x |
| 2026-02-12 | 3.21x |
| 2026-02-11 | 3.22x |
| 2026-02-10 | 3.12x |
| 2026-02-09 | 3.08x |
| 2026-02-06 | 3.08x |
| 2026-02-05 | 3.05x |
| 2026-02-04 | 3.04x |
| 2026-02-03 | 2.99x |
| 2026-02-02 | 2.99x |
| 2026-01-30 | 3.01x |
| 2026-01-29 | 2.99x |
| 2026-01-28 | 2.98x |
| 2026-01-27 | 2.99x |
| 2026-01-26 | 3.02x |
| 2026-01-23 | 3.00x |
| 2026-01-22 | 3.02x |
| 2026-01-21 | 3.00x |
| 2026-01-20 | 3.01x |
| 2026-01-16 | 3.02x |
| 2026-01-15 | 3.05x |
| 2026-01-14 | 3.07x |
| 2026-01-13 | 3.04x |
| 2026-01-12 | 3.12x |
| 2026-01-09 | 3.16x |
| 2026-01-08 | 3.19x |
| 2026-01-07 | 3.15x |
| 2026-01-06 | 3.20x |
| 2026-01-05 | 3.15x |
| 2026-01-02 | 3.09x |
| 2025-12-31 | 3.08x |
| 2025-12-30 | 3.10x |
| 2025-12-29 | 3.10x |
| 2025-12-26 | 3.10x |
| 2025-12-24 | 3.09x |
| 2025-12-23 | 3.07x |
| 2025-12-22 | 3.08x |
| 2025-12-19 | 3.06x |
| 2025-12-18 | 3.09x |
| 2025-12-17 | 3.12x |
| 2025-12-16 | 3.11x |
| 2025-12-15 | 3.15x |
| 2025-12-12 | 3.12x |
| 2025-12-11 | 3.15x |
| 2025-12-10 | 3.16x |
| 2025-12-09 | 3.14x |
| 2025-12-08 | 3.15x |
| 2025-12-05 | 3.19x |
| 2025-12-04 | 3.16x |
| 2025-12-03 | 3.16x |
| 2025-12-02 | 3.19x |
| 2025-12-01 | 3.20x |
| 2025-11-28 | 3.27x |
| 2025-11-26 | 3.27x |
| 2025-11-25 | 3.26x |
| 2025-11-24 | 3.17x |
| 2025-11-21 | 3.14x |
| 2025-11-20 | 3.06x |
| 2025-11-19 | 3.07x |
| 2025-11-18 | 3.06x |
| 2025-11-17 | 3.05x |
| 2025-11-14 | 3.08x |
| 2025-11-13 | 3.10x |
| 2025-11-12 | 3.09x |
| 2025-11-11 | 3.05x |
| 2025-11-10 | 3.05x |
| 2025-11-07 | 3.05x |
| 2025-11-06 | 3.05x |
| 2025-11-05 | 3.02x |
| 2025-11-04 | 3.51x |
| 2025-11-03 | 3.42x |
| 2025-10-31 | 3.44x |
| 2025-10-30 | 3.42x |
| 2025-10-29 | 3.42x |
| 2025-10-28 | 3.46x |
| 2025-10-27 | 3.51x |
| 2025-10-24 | 3.50x |
| 2025-10-23 | 3.51x |
| 2025-10-22 | 3.53x |
| 2025-10-21 | 3.49x |
| 2025-10-20 | 3.50x |
| 2025-10-17 | 3.48x |
| 2025-10-16 | 3.42x |
| 2025-10-15 | 3.41x |
| 2025-10-14 | 3.39x |
| 2025-10-13 | 3.30x |
| 2025-10-10 | 3.29x |
| 2025-10-09 | 3.36x |
| 2025-10-08 | 3.39x |
| 2025-10-07 | 3.40x |
| 2025-10-06 | 3.40x |
| 2025-10-03 | 3.45x |
| 2025-10-02 | 3.41x |
| 2025-10-01 | 3.40x |
| 2025-09-30 | 3.39x |
| 2025-09-29 | 3.38x |
| 2025-09-26 | 3.38x |
| 2025-09-25 | 3.35x |
| 2025-09-24 | 3.40x |
| 2025-09-23 | 3.43x |
| 2025-09-22 | 3.47x |
| 2025-09-19 | 3.43x |
| 2025-09-18 | 3.43x |
| 2025-09-17 | 3.42x |
| 2025-09-16 | 3.40x |
| 2025-09-15 | 3.45x |
| 2025-09-12 | 3.50x |
| 2025-09-11 | 3.53x |
| 2025-09-10 | 3.49x |
| 2025-09-09 | 3.52x |
| 2025-09-08 | 3.55x |
| 2025-09-05 | 3.57x |
| 2025-09-04 | 3.55x |
| 2025-09-03 | 3.55x |
| 2025-09-02 | 3.55x |
| 2025-08-29 | 3.58x |
| 2025-08-28 | 3.55x |
| 2025-08-27 | 3.60x |
| 2025-08-26 | 3.62x |
| 2025-08-25 | 3.61x |
| 2025-08-22 | 3.62x |
| 2025-08-21 | 3.54x |
| 2025-08-20 | 3.57x |
| 2025-08-19 | 3.54x |
| 2025-08-18 | 3.49x |
| 2025-08-15 | 3.50x |
| 2025-08-14 | 3.48x |
| 2025-08-13 | 3.51x |
| 2025-08-12 | 3.47x |
| 2025-08-11 | 3.43x |
| 2025-08-08 | 3.41x |
| 2025-08-07 | 3.39x |
| 2025-08-06 | 3.12x |
| 2025-08-05 | 3.14x |
| 2025-08-04 | 3.15x |
| 2025-08-01 | 3.10x |
| 2025-07-31 | 3.13x |
| 2025-07-30 | 3.17x |
| 2025-07-29 | 3.22x |
| 2025-07-28 | 3.24x |
| 2025-07-25 | 3.28x |
| 2025-07-24 | 3.27x |
| 2025-07-23 | 3.28x |
| 2025-07-22 | 3.26x |
| 2025-07-21 | 3.15x |
| 2025-07-18 | 3.17x |
| 2025-07-17 | 3.21x |
| 2025-07-16 | 3.20x |
| 2025-07-15 | 3.19x |
| 2025-07-14 | 3.19x |
| 2025-07-11 | 3.19x |
| 2025-07-10 | 3.22x |
| 2025-07-09 | 3.22x |
| 2025-07-08 | 3.18x |
| 2025-07-07 | 3.15x |
| 2025-07-03 | 3.18x |
| 2025-07-02 | 3.18x |
| 2025-07-01 | 3.19x |
| 2025-06-30 | 3.12x |
| 2025-06-27 | 3.12x |
| 2025-06-26 | 3.13x |
| 2025-06-25 | 3.16x |
| 2025-06-24 | 3.15x |
| 2025-06-23 | 3.13x |
| 2025-06-20 | 3.12x |
| 2025-06-18 | 3.10x |
| 2025-06-17 | 3.09x |
| 2025-06-16 | 3.14x |
| 2025-06-13 | 3.12x |
| 2025-06-12 | 3.17x |
| 2025-06-11 | 3.20x |
| 2025-06-10 | 3.21x |
| 2025-06-09 | 3.16x |
| 2025-06-06 | 3.15x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. (ZBH), along with its global subsidiaries, operates as a leading player in the musculoskeletal healthcare sector. The company extends its reach across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. ZBH is responsible for the design, manufacturing, and marketing of a wide array of orthopedic reconstructive solutions, including prominent knee and hip replacement systems. Their offerings also encompass Specialized Enabling Technologies (S.E.T.) products, which cover areas such as sports medicine, biologics, foot and ankle care, extremity treatments, and trauma management. Furthermore, the company provides medical devices and surgical instruments specifically for spinal conditions, alongside products for facial and cranial reconstruction. A unique part of their portfolio includes systems designed to stabilize and fixate chest bones, facilitating recovery or reconstruction following open-heart surgery, traumatic injuries, or congenital chest deformities. The company's product lines also feature a comprehensive range of dental solutions, such as reconstructive implants, prosthetics, and regenerative materials. Additionally, they are involved in robotic surgical systems, general surgical instruments, and bone cements. These advanced products and solutions are primarily utilized to address conditions in patients suffering from disorders or injuries affecting bones, joints, and their associated soft tissues. Zimmer Biomet caters to a broad clientele, including orthopedic, neuro-, and oral surgeons, dentists, hospitals, independent distributors, healthcare suppliers, and various other medical specialists. Their network further encompasses agents, healthcare purchasing organizations, and group buying alliances. Originally established in 1927, the enterprise was initially known as Zimmer Holdings, Inc., before rebranding as Zimmer Biomet Holdings, Inc. in June 2015. Its corporate headquarters are situated in Warsaw, Indiana.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ivan Tornos